239 related articles for article (PubMed ID: 31092275)
21. Overexpression of SDF-1 activates the NF-κB pathway to induce epithelial to mesenchymal transition and cancer stem cell-like phenotypes of breast cancer cells.
Kong L; Guo S; Liu C; Zhao Y; Feng C; Liu Y; Wang T; Li C
Int J Oncol; 2016 Mar; 48(3):1085-94. PubMed ID: 26782945
[TBL] [Abstract][Full Text] [Related]
22. 2-Methoxyestradiol inhibits the proliferation and migration and reduces the radioresistance of nasopharyngeal carcinoma CNE-2 stem cells via NF-κB/HIF-1 signaling pathway inactivation and EMT reversal.
Wu SL; Li YJ; Liao K; Shi L; Zhang N; Liu S; Hu YY; Li SL; Wang Y
Oncol Rep; 2017 Feb; 37(2):793-802. PubMed ID: 28000883
[TBL] [Abstract][Full Text] [Related]
23. CXCL8 induces epithelial-mesenchymal transition in colon cancer cells via the PI3K/Akt/NF-κB signaling pathway.
Shen T; Yang Z; Cheng X; Xiao Y; Yu K; Cai X; Xia C; Li Y
Oncol Rep; 2017 Apr; 37(4):2095-2100. PubMed ID: 28259918
[TBL] [Abstract][Full Text] [Related]
24. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
25. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
26. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.
Meng J; Zhang XT; Liu XL; Fan L; Li C; Sun Y; Liang XH; Wang JB; Mei QB; Zhang F; Zhang T
Cell Signal; 2016 Nov; 28(11):1673-82. PubMed ID: 27449264
[TBL] [Abstract][Full Text] [Related]
27. IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway.
Yang J; Zeng Z; Peng Y; Chen J; Pan L; Pan D
Histochem Cell Biol; 2014 Oct; 142(4):401-10. PubMed ID: 24770666
[TBL] [Abstract][Full Text] [Related]
28. Micafungin exerts antitumor effect on breast cancer and osteosarcoma through preventing EMT in tumor cells in an USP7/AKT/GSK-3β pathway-dependent manner.
Wang QL; Wang L; Li QY; Li HY; Lin L; Wei D; Xu JY; Luo XJ
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4447-4459. PubMed ID: 38108838
[TBL] [Abstract][Full Text] [Related]
29. NDRG2 suppresses proliferation, migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells through regulating the AKT/XIAP signaling pathway.
Yang CL; Zheng XL; Ye K; Ge H; Sun YN; Lu YF; Fan QX
Int J Biochem Cell Biol; 2018 Jun; 99():43-51. PubMed ID: 29530788
[TBL] [Abstract][Full Text] [Related]
30. Cirsiliol Suppressed Epithelial to Mesenchymal Transition in B16F10 Malignant Melanoma Cells through Alteration of the PI3K/Akt/NF-κB Signaling Pathway.
Prasad P; Vasas A; Hohmann J; Bishayee A; Sinha D
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30708951
[TBL] [Abstract][Full Text] [Related]
31. Dichotomy effects of Akt signaling in breast cancer.
Peng Z; Weber JC; Han Z; Shen R; Zhou W; Scott JR; Chan MW; Lin HJ
Mol Cancer; 2012 Aug; 11():61. PubMed ID: 22917467
[TBL] [Abstract][Full Text] [Related]
32. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition.
Prasad CP; Chaurasiya SK; Guilmain W; Andersson T
J Exp Clin Cancer Res; 2016 Sep; 35(1):144. PubMed ID: 27623766
[TBL] [Abstract][Full Text] [Related]
33. Low doses of PEG-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the PI3K/AKT-driven signaling axis to suppress cellular transformation by inhibiting growth and EMT.
Kaushik NK; Kaushik N; Yoo KC; Uddin N; Kim JS; Lee SJ; Choi EH
Biomaterials; 2016 May; 87():118-130. PubMed ID: 26921841
[TBL] [Abstract][Full Text] [Related]
34. Astragaloside IV inhibits TGF-β1-induced epithelial-mesenchymal transition through inhibition of the PI3K/Akt/NF-κB pathway in gastric cancer cells.
Zhu J; Wen K
Phytother Res; 2018 Jul; 32(7):1289-1296. PubMed ID: 29480652
[TBL] [Abstract][Full Text] [Related]
35. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway.
Colavito SA; Zou MR; Yan Q; Nguyen DX; Stern DF
Breast Cancer Res; 2014 Sep; 16(5):444. PubMed ID: 25252859
[TBL] [Abstract][Full Text] [Related]
36. BDE-99 (2,2',4,4',5-pentabromodiphenyl ether) triggers epithelial-mesenchymal transition in colorectal cancer cells via PI3K/Akt/Snail signaling pathway.
Wang F; Ruan XJ; Zhang HY
Tumori; 2015; 101(2):238-45. PubMed ID: 25908029
[TBL] [Abstract][Full Text] [Related]
37. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.
Qin G; Xu F; Qin T; Zheng Q; Shi D; Xia W; Tian Y; Tang Y; Wang J; Xiao X; Deng W; Wang S
Oncotarget; 2015 Dec; 6(39):41794-808. PubMed ID: 26540629
[TBL] [Abstract][Full Text] [Related]
38. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
39. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
[TBL] [Abstract][Full Text] [Related]
40. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2.
Wei L; Li K; Pang X; Guo B; Su M; Huang Y; Wang N; Ji F; Zhong C; Yang J; Zhang Z; Jiang Y; Liu Y; Chen T
J Exp Clin Cancer Res; 2016 Oct; 35(1):166. PubMed ID: 27769315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
